TEST:

BluePrint

P2, N=30, Recruiting, Legacy Health System | Not yet recruiting --> Recruiting

P2, N=51, Active, not recruiting, The Methodist Hospital Research Institute | N=39 --> 51 | Trial completion date: Dec 2025 --> Dec 2028

P2, N=30, Not yet recruiting, Legacy Health System

Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.

3D preoperative planning demonstrated moderate to high accuracy for glenoid component selection but lower concordance for humeral stem size. Intraoperative adjustments were mainly related to metaphyseal bone quality and soft tissue tension. Future improvements in planning software should incorporate bone mineral density and humeral osteotomy variability to enhance predictive accuracy.

Thermodynamic and electrochemical evaluation indicated greater stability and electron flow in co-culture reactors (R9:ΔG = -42.29 kJ) compared to monocultures. Collectively, this study presents a scalable hybrid bioelectrochemical strategy leveraging species-specific metabolic roles and electron-steering to facilitate high-yield, selective SA production, offering a promising blueprint for sustainable carbon-based biomanufacturing.

MMP, particularly its selected Mueller matrix elements, combined with clinical biomarkers show promise in distinguishing LBCS as validated against BluePrint®. By detecting subtle differences in tissue morphology, this approach may enhance breast cancer prognosis and help guide treatment decisions.

P=N/A, N=44, Completed, Stryker Trauma and Extremities | Recruiting --> Completed

Our results provide critical references for the efficacy and biomarkers of de-escalated neoadjuvant therapy in HER2-positive breast cancer. National Natural Science Foundation of China and Natural Science Foundation of Jiangsu Province.

"Agendia®, Inc...today announced the presentation of four major abstracts in collaboration with independent investigators at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 29th– June 3rd, 2025, in Chicago, Illinois. "

Our study confirms that patients treated with SLN do not show a higher risk of LRNR compared to ALND. LRNR is often diagnosed incidentally. Younger age, residual disease post-NAC, no regional radiation, stage II, and initial LN involvement were more represented, as well as patients with endocrine sensitive disease classified as low-risk luminal A by MB. Ongoing trials, including SOUND, INSEMA, and BOOG 2013-08, are further exploring axillary surgery de-escalation.

This study identified gene expression signatures associated with breast cancer risk and molecular subtypes. These findings provide insights into the biological processes that may drive breast cancer progression and could inform the development of prognostic biomarkers and personalized therapeutic strategies.